M&A & Funding

In-depth analysis of Bayer's acquisition of Perfuse Therapeutics for up to $2.45 billion, marking its return to M&A after a 5-year drought. Covers the PER-001 intravitreal implant for glaucoma and diabetic retinopathy, deal structure, endothelin receptor antagonism mechanism, the growing drug-device combination product market, and what it means for ophthalmic medtech manufacturers and investors.

Sun Pharmaceutical Industries agreed to acquire Organon & Co. for $11.75 billion in the largest pharmaceutical deal of 2026 and India's largest overseas pharma acquisition. Covers deal structure, Organon's portfolio of women's health products (Nexplanon, NuvaRing) and biosimilars (Hadlima, Renflexis), the drug-device combination products involved, regulatory considerations for combination products, and what the deal means for the women's health and biosimilar device landscape.

In-depth analysis of Danaher's $9.9 billion acquisition of Masimo, the largest medtech deal of 2026. Covers deal structure, strategic rationale, regulatory and antitrust considerations, competitive landscape impact on patient monitoring, and what it means for device manufacturers, hospitals, and investors.

The medical device CDMO market is projected to grow from $134.65 billion in 2025 to $354.60 billion by 2033 at 13.12% CAGR. This guide covers market size, growth drivers, key players (Jabil, Integer, Flex, Plexus), M&A trends, and how to choose the right contract manufacturing partner.

A data-driven analysis of the AI medical device investment boom — covering the Medtronic/CathWorks deal, Zimmer Biomet/Monogram acquisition, HistoSonics' $2.25B valuation, record FDA AI clearances, and how AI now drives 55% of all health tech funding in 2025-2026.

Comprehensive analysis of the Middle East & North Africa medical device market — $24.6B in 2025 growing to $35B by 2032 at 5.1% CAGR. Saudi Arabia's $35.5B Global Health Exhibition deals, 400 GCC healthcare transactions (2021–2025), UAE $3.18B market, Egypt $4.37B, digital health at 19.6% CAGR, and smart devices growing at 10.16% CAGR.

A data-driven tracker of every major medtech M&A deal in 2025 and 2026 — from Abbott's $21B Exact Sciences acquisition to Boston Scientific's $14.5B Penumbra buy — with deal values, strategic rationale, and industry trends.

A data-driven analysis of why cardiovascular devices dominate medtech M&A — covering the Stryker/Inari, Boston Scientific/Penumbra, and Medtronic/CathWorks deals, the PFA revolution, structural heart innovation, and the forces driving CV dealmaking in 2025-2026.

An in-depth analysis of how the Federal Trade Commission is reshaping medtech dealmaking — from blocking the Edwards/JenaValve TAVR deal to the GTCR/Surmodics outcome, HSR filing changes, and the rise of state-level mini-HSR laws.

A comprehensive guide to medical device company valuation in 2025-2026 — covering EBITDA and revenue multiples by subsector, valuation methods for pre-revenue and commercial-stage companies, deal structures including earn-outs and CVRs, and the due diligence process.

A practical guide to raising venture capital for medical device startups in 2026 — covering typical raise amounts by stage, what investors evaluate, hot subsectors, the VC ecosystem, and how to position for a successful fundraise.

A comprehensive analysis of the wave of medtech divestitures and spinoffs reshaping the industry — from BD's $17.5B Waters deal to J&J's DePuy Synthes separation, Siemens Healthineers deconsolidation, and Medtronic's MiniMed IPO.

A comprehensive analysis of the medtech and healthcare IPO landscape in 2026 — from Medline's record $6.3B listing and Medtronic's MiniMed Diabetes spinoff IPO to digital health debuts, SPAC resurgence, and what's in the pipeline.

A deep dive into private equity's growing role in medtech — from Blackstone and TPG's landmark $18.3B Hologic take-private to buy-and-build platforms, CDMO acquisitions, the record Medline IPO exit, and PE dry powder deployment strategies.

A comprehensive analysis of the surgical robotics M&A and funding landscape in 2025-2026 — from Intuitive's dominance to the rise of challengers like CMR Surgical, Medtronic Hugo, J&J OTTAVA, and Distalmotion, plus the shift from VC-backed pioneers to PE-led consolidation.

A comprehensive guide to medical device mergers & acquisitions, venture capital funding, and startup investment — covering regulatory due diligence, valuation methods, deal structures, and market trends.